Fees for the Recordkeeping System for Ephedrine and Related Compounds
Summary
HB 237 amends Florida’s ephedrine and related-compounds retail sale law to require manufacturers of ephedrine or related compounds sold in the state to pay a monthly fee beginning July 1, 2025. The fee is directed to the administrator of the electronic recordkeeping system approved by the Department of Law Enforcement, and the administrator is authorized to set the fee level. Manufacturers must also provide written proof of payment to the Department of Law Enforcement upon request.
The bill also updates the statute’s applicability and enforcement provisions. It clarifies that the general exemption for licensed manufacturers does not apply to manufacturers subject to the new fee requirement, and it adds violations of the new fee provision to the statute’s penalty structure. As a result, noncompliance can be punished as a second-degree misdemeanor for a first offense, a first-degree misdemeanor for a second offense, and a third-degree felony for a third or subsequent offense.
Impact
HB 237 would shift the cost of operating Florida’s electronic recordkeeping system for ephedrine and related compounds from the state or other system users to manufacturers of those products. It amends section 893.1495, Florida Statutes, by creating a new manufacturer fee requirement, authorizing the system administrator to establish the fee schedule, and tying compliance to documentation that may be requested by the Department of Law Enforcement. The bill also expands the statute’s penalty provisions to cover violations of the new fee requirement, affecting manufacturers, distributors, and any individuals subject to the retail-sale controls in the section.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, support, or opposition in the available materials. Based on the bill text alone, the measure appears administrative and enforcement-oriented rather than policy-expansive, suggesting a likely focus on funding and compliance for an existing controlled-substance tracking system. The absence of recorded legislative history makes the overall sentiment difficult to assess beyond the bill’s technical, regulatory character.
Contention
The main point of potential contention is the new monthly fee imposed on manufacturers, which could be viewed as a cost burden on businesses that produce ephedrine or related compounds. Another possible issue is the delegation of fee-setting authority to the system administrator, which gives an outside entity discretion over the amount manufacturers must pay. Finally, the bill’s addition of criminal penalties for violations of the fee requirement may raise concerns about whether nonpayment or documentation failures should be treated as misdemeanor or felony conduct.